Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Age 3 to 21~* Performance status of Karnofsky 50-100% OR Lansky 50-100%~* Absolute neutrophil count greater than 1,000/mm3~* Platelet count greater than 100,000/mm3 (transfusion independent)~* Hemoglobin greater than 8 g/dL (transfusion allowed)~* Bilirubin no greater than 1.5 times normal for age~* SGPT less than 3 times normal for age~* Albumin at least 2 g/dL~* Creatinine less than 1.5 times normal for age OR Glomerular filtration rate greater than 70 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 6 months after study participation~* Stratum I~  * Newly diagnosed diffuse intrinsic brainstem malignant glioma~ * No disseminated disease~ * No radiographic evidence of intratumoral hemorrhage before or during radiotherapy~ * No prior chemotherapy (beyond routine corticosteroids)~ * No prior irradiation~ * Must not be receiving enzyme-inducing anticonvulsant drugs~* Stratum II~  * Histologically confirmed recurrent or refractory anaplastic astrocytoma, glioblastoma multiforme, or other high-grade glioma (including recurrent brain stem glioma~ * No intratumoral hemorrhage unrelated to prior surgical procedure~ * No myelosuppressive chemotherapy within 3 weeks (6 weeks if a nitrosourea agent) of study entry~ * No prior imatinib mesylate~ * At least 3 months since prior craniospinal radiotherapy (18 Gy or more)~ * At least 8 weeks since prior local radiotherapy to primary tumor~ * At least 2 weeks since prior focal radiotherapy for symptomatic~ * At least 3 months since prior bone marrow transplantation~ * Neurological deficits allowed if stable for at least 1 week prior to study~Exclusion Criteria~* Receiving other anticancer or experimental drug therapy.~* Ongoing uncontrolled infection.~* Significant cardiac, hepatic, gastrointestinal, renal, pulmonary, or psychiatric disease.~* Deep venous or arterial thrombosis within 6 weeks of registration.~* Taking warfarin.~* Newly diagnosed diffuse intrinsic brainstem malignant glioma with disseminated disease (stratum I)~* Intratumoral hemorrhage

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).